ЛИТЕРАТУРА

1. Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S, Escobar-Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab. 2000; 85:2434-8.

2. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004; 89:2745-9.

3. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianateli TC, Spina GG, et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J CHn Endocrinol Metab. 1999; 84:4006-11.

4. March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ, Davies MJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod. Hum Reprod. 2010 Feb;25(2):544-51.

5. Moran C, Tena G, Moran S, Ruiz P, Reyna R, X. D. Prevalence of polycystic ovary syndrome and related disorders in Mexican women. Gynecol Obstet Invest. 2010; 69:274-80.

6. Yildiz BO, Bozdag G, Yapici Z, Esinler I, Yarali H. Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. Hum Reprod. 2012 Oct; 27(10):3067-73.

7. Azziz R, Sanchez LA, Knochenhauer ES, Moran C, Lazenby J, Stephens КС, Taylor K, Boots LR. Androgen excess in women: experience with over 1000 consecutive patients J Clin Endocrinol Metab. 2004 Feb;89(2):453-62.

8. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE, Witchel SF The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 2009 Feb;91(2):456-88.

9. Carmina E, Rosato F, Janni A, Rizzo M, Longo RA. Extensive clinical experience: relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism J Clin Endocrinol Metab. 2006 Jan; 91(l):2-6.

10. Chen X, Yang D, Mo Y, Li L, Chen Y, Huang Y. Prevalence of polycystic ovary syndrome in unselected women from southern China. Eur J Obstet Gynecol Reprod Biol. 2008 Jul;139(l):59-64.

11. Hardiman P, Pillay ОС, Atiomo W. Polycystic ovary syndrome and endometrial carcinoma. Lancet 2003; 361:1810.

12. Gadducci A, Gargini A, Palla E, et al. Polycystic ovary syndrome and gynecological cancers: is there a link? Gynecol Endocrinol 2005; 20:200.

13. Glucose intolerance in polycystic ovary syndrome - a position statement of the Androgen Excess Society. J Clin Endocrinol Metab. 2007 Dec; 92(12):4546-56.

14. Wild S, Pierpoint T, McKeigue P, and Jacobs H. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin. Endocrinol. 2000 52: 595-600.

15. Randeva HS, Tan BK, Weickert MO, et al. Cardiometabolic aspects of the poly-cystic ovary syndrome. Endocr Rev 2012; 33:812.

16. Zawadzki J, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens J, Haseltine Haseltine F, Haseltine G, eds. Polycystic Ovary Syndrome. 1st ed. Oxford, England: Blackwell Scientific; 1992:377-384.

17. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19:41-7.

18. Azziz R, Carmina E, Dewailly D et al. Positions statement: Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab. 2006 Nov; 91(11):4237-45.

19. http://prevention.nih.gov/workshops/2012/pcos/docs/FinalReport.pdf.

20. Escobar-Morreale HF1, Carmina E, Dewailly D et al. Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society. Hum Reprod Update. 2012 Mar-Apr; 18(2):146-70.

21. Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R, Welt CK. Diagnosis and treatment of polycystic ovary syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2013 Dec; 98 (12):4565-9.

22. Cheewadhanaraks S, Peeyananjarassri K, Choksuchat С Clinical diagnosis of hirsutism in Thai women. J Med Assoc Thai. 2004 May;87(5):459-63.

23. Yildiz BO, Bolour S, Woods K, Moore A, Azziz R. Visually scoring hirsutism. HumReprod Update 2010; 16:51-64.

24. Karrer-Voegeli S, Rey F, Reymond MJ, Meuwly JY, Gaillard RC, Gomez F. Androgen dependence of hirsutism, acne, and alopecia inwomen: retrospective analysis of 228 patients investigated for hyperandrogenism. Medicine (Baltimore). 2009; 88:32-45.

25. Rosner W. Position statement: Utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. J Clin Endocrinol Metab. 2007 Feb; 92(2):405-13.

26. Stanczyk F.Z. Diagnosis of hyperandrogenism: Biochemical criteria Best Practice & Research Clinical Endocrinology & Metabolism 2006 Vol. 20, No. 2, pp. 177-191.

27. Legro RS, Schlaff WD, Diamond MP et al. Total testosterone assays in women with polycystic ovary syndrome: precision and correlation with hirsutism. J Clin Endocrinol Metab 2010 95:5305-5313).

28. Dewailly D, Lujan ME, Carmina E et al. Definition and significance of polycystic ovarian morphology: a task force report from the Androgen Excess and Polycystic Ovary Syndrome Society. Hum Reprod Update. 2014 May-Jun;20(3):334-52.

29. Ladenson P.W., Singer P.A., Ain K.B. et al. American Thyroid Association guidelines for detection of thyroid dysfunction Arch Intern Med 2000 160(11): 1573-1575.

30. Oxford handbook of endocrinology and diabetes. Ed by Wass J., Owen K., The 3d edition. 2014 Oxford University Press, p 75.

31. Melmed Sh., Casanueva F.F., Hoffman A.R. et al. Diagnosis and Treatment of Hyperprolactinemia: An Endocrine Society Clinical Practice Guideline J. Clin. Endocrinol. Metab. 2011 96(2): 273-288

32. Speiser PW, Azziz R, Baskin LS et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline J Clin Endcrinol Metab, September 2010, Vol. 95(9):4133-4160.

33. Veltman-Verhulst SM, Goverde AJ, van Haeften TW, Fauser BCJM. Fasting glucose measurement as a potential first step screening for glucose metabolism abnormalities in women with anovulatory polycystic ovary syndrome. Hum Reprod 2013;28:2228-2234).

34. Alberti KG, Eckel RH, Grundy SM et al. Harmonizing the Metabolic Syndrome A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity Circulation. 2009;120(16): 1640-5.

35. Wild RA, Carmina E, Diamanti-Kandarakis E, et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AEPCOS) Society. J Clin Endocrinol Metab. 2010; 95:2038-2049.

36. Medical eligibility criteria for contraceptive use. WHO: 4th ed. 2010.

37. Fauser BC1, Tarlatzis ВС, Rebar RW et al. Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril. 2012 Jan; 97(l):28-38.

38. Katsambas AD, Dessinioti C. Hormonal therapy for acne: why not as first line therapy? facts and controversies. Clin Dermatol 2010; 28:17.

39. Apovian CM, Aronne LJ, Bessesen DH et al. Pharmacological management of obesity:an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015 Feb;100(2):342-62.

40. Consensus on infertility treatment related to polycystic ovary syndrome. Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Hum Reprod. 2008 Mar; 23(3):462-77.

41. Imani Bl, Eijkemans MJ, te Velde ER et al. A nomogram to predict the probability of live birth after clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. Fertil Steril. 2002 Jan;77(l):91-7.

42. NIH/NICHD Reproductive Medicine Network. Effect of letrozole versus clomiphene on live birth in women with anovulatory infertility due to polycystic ovary syndrome (PCOS): a randomized double- blind multicenter trial. Fertil Steril. 2013; 100(3 suppl):S51.

43. Farquhar C, Brown J, Marjoribanks J. Laparoscopic drilling by diathermy or laser for ovulation induction in anovulatory polycystic ovary syndrome. Cochrane Database Syst Rev. 2012Junl3;6:CD001122.

44. Bayram N, vanWely M, Kaaijk EM, Bossuyt PM, van derVeen F. Using an electrocautery strategy or recombinant follicle stimulating hormone to induce ovulation in polycystic ovary syndrome: randomised controlled trial. BMJ 2004; 328:192.

45. Tso LO, Costello MF, Albuquerque LE, Andriolo RB, Freitas V. Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2009;2:CD006105.

46. Zhu RR, Xiao SQ, Zhao JZ, Lin J, Wang PY, Jin CC, Jin WM [Comparison of the efficiency between in-vitro maturation and in-vitro fertilization after early follicular phase GnRH agonist down-regulation in infertile women with polycystic ovary syndrome]. Zhonghua Fu Chan Ke Za Zhi. 2013 N ov; 48(11):833-7.

47. Atkins D, Best D, Briss PA, et al. 2004 Grading quality of evidence and strength of recommendations. BMJ 2004; 328: 1490.